Compare GLUE & FUBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLUE | FUBO |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 2020 |
| Metric | GLUE | FUBO |
|---|---|---|
| Price | $16.03 | $2.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $19.50 | $5.35 |
| AVG Volume (30 Days) | 976.6K | ★ 10.4M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.25 | ★ 0.34 |
| Revenue | $181,538,000.00 | ★ $1,616,726,000.00 |
| Revenue This Year | $81.52 | N/A |
| Revenue Next Year | N/A | $5.99 |
| P/E Ratio | $62.71 | ★ $7.73 |
| Revenue Growth | ★ 1112.27 | 1.70 |
| 52 Week Low | $3.50 | $1.21 |
| 52 Week High | $19.17 | $6.45 |
| Indicator | GLUE | FUBO |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 33.07 |
| Support Level | $14.64 | $2.55 |
| Resistance Level | $19.17 | $2.76 |
| Average True Range (ATR) | 1.23 | 0.11 |
| MACD | -0.29 | 0.01 |
| Stochastic Oscillator | 30.91 | 28.05 |
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.